Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Gastrointestinal 2Endocrine 2CNS 2Breast 2Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Lung Neoplasms 4Carcinoma, Medullary 4Breast Neoplasms 4Thyroid Neoplasms 3Thyroid Cancer, Papillary 3Colonic Neoplasms 3Thyroid Diseases 2Thoracic Neoplasms 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Neoplasms by Site 2Neoplasms 2Lung Diseases 2Head and Neck Neoplasms 2Endocrine System Diseases 2Endocrine Gland Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Bronchogenic 2Bronchial Neoplasms 2Sexual Dysfunction, Physiological 1Sarcoma 1Pancreatic Neoplasms 1Myofibromatosis 1Gastrointestinal Neoplasms 1Eunuchism 1Erectile Dysfunction 1

Interventions

Pemetrexed 7Carboplatin 7Cisplatin 5pembrolizumab 4durvalumab 4osimertinib 3Paclitaxel 3selpercatinib 2pralsetinib 2cobimetinib 2Radiosurgery 2Erlotinib Hydrochloride 2130-nm albumin-bound paclitaxel 2trametinib 1taletrectinib 1sotorasib 1repotrectinib 1patritumab 1napabucasin 1glutathione pegylated liposomal doxorubicin 1ficlatuzumab 1exemestane 1enzalutamide 1entinostat 1dabrafenib 1ceralasertib 1cemiplimab 1camrelizumab 1atezolizumab 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms by Site × selpercatinib × Thoracic × Clear all
NCT03157128 2026-04-16

LIBRETTO-001

Eli Lilly and Company

Phase 1/2 Active not recruiting
857 enrolled 24 charts 3 FDA
BreastCNSEndocrineGastrointestinalHead & NeckThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Central Nervous System Neoplasms, Carcinoma, Medullary

NCT03899792 2026-01-06

LIBRETTO-121

Eli Lilly and Company

Phase 1/2 Active not recruiting
36 enrolled 13 charts 2 FDA
BreastCNSEndocrineGastrointestinalHead & NeckSarcomaThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Central Nervous System Neoplasms, Myofibromatosis, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡